Heme production is a vital metabolic process that occurs in the bone marrow and liver. Porphyrins are unused by-products of this biosynthetic process and normally occur in urine and other body fluids in low concentrations.
Introduction
The ability to recognize disease in its early stages before overt symptoms appear is a continuing goal of medical science. Accomplishing this goal often results in treatment which arrests or prevents further development of the disease.
Monitoring various biochemical functions may provide this type of information. Our interest in this area has been in the evaluation of the heme biosynthetic pathway under the influence of environmental chemicals via urinary porphyrin analyses. This paper describes the heme biosynthetic pathway and the changes that may occur with exposure to polyhalogenated aromatic compounds. The importance of recognizing various urinary porphyrin patterns by high-performance liquid chromatography (HPLC) is discussed, and demonstrated, and suggestions are made for using these patterns as a diagnostic tool. 
Heme Biosynthesis
The production of heme is a vital metabolic process, and disturbances in the biosynthesis of heme can lead to a group of diseases known as the porphyrias. Heme is produced principally in the bone marrow and the liver.
Most heme (85%) is made in the bone marrow and is used to make hemoglobin for new red blood cells (1) . About 15% of the body's heme production occurs in the liver. This heme is used in making enzymes, including microsomal cytochrome P450 and other cytochromes. The biosynthesis of heme, as depicted in Figure 1 , begins in the mitochondrion of a cell with the condens,-tion of glycine and succinate to produce 8-aminolevulinic acid (ALA). Two molecules of ALA are used to form porphobilinogen (PBG), and four molecules of PBG are condensed to form uroporphyrinogen (UPG). This molecule is successively decarboxylated and oxidized to protoporphyrin (PP), which is oxidized and converted to heme by insertion of a ferrous ion.
Porphyrins are by-products of the biosynthetic pathway to heme and are derived from oxidation of the porphyrinogens. The body produces two . CHP may be a subclinical which these two porphyrins are dominant is particularly the urinary porphyrin excretion is diagnostic of this enzyme deficiency and PCT (6-9).
There are two forms of PCT: familial or hereditary and acquired or chemically induced (10) (11) (12) . It is possible and important to distinguish between these two forms. In the hereditary form, at least some family members exhibit overt or subclinical signs of PCT. Additionally, the activity of the enzyme UPD is substantially decreased in the liver and in the erythrocytes. In the chemically induced porphyria, there is no evidence of PCT among relatives, and UPD activity is depressed in the liver but is normal in the erythrocytes. Measuring this erythrocyte enzyme activity in subjects with abnormal porphyrin patterns is necessary to distinguish between hereditary and chemically induced porphyria.
Various chemicals have been reported to induce PCT and other subclinical states of CHP in humans. These include alcohol, estrogens, hexachlorobenzene, 2,3,7,8-tetrachlorodibenzo-p-dioxin, methyl chloride, lindane polychlorinated biphenyls (PCBs), polybrominated biphenyls (PBBs) and vinyl chloride. Alcohol and estrogens are the most common chemicals which have been observed to cause PCT (1, 3, (13) (14) (15) . In Turkey in the 1950s, several thousand persons contracted PCT and a "mixed" porphyria from exposure to hexachlorobenzene (16) . Even after 25 years, many of the people still exhibit signs and symptoms of this porphyria. In Czechoslovakia, workers from a 2,4,5-T production plant became ill from exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (17) . At the initial investigation, 20% had PCT and another 21% had uroporphyrinuria, but 10 years later these signs and symptoms were rare, Isolated cases of PCT and porphyrinuria from methyl chloride and lindane have also been reported (18) (19) (20) . Polychlorinated biphenyls (PCBs), PBBs, and vinyl chloride have been reported to produce subelinical CHP (21-23).
Monitoring Urinary Porphyrin Patterns
Determining urinary porphyrin patterns is an important aid in diagnosing porphyria (6) (7) (8) (9) . In the early 1970s, Doss pointed out that thin-layer chromatography (TLC) provided quantitative and qualitative data that allowed PCT to be diagnosed from a single urine sample (6) . This same author developed the theory that CHP, whether hereditary or acquired by chemical exposure, developed in stages, and these stages are recognizable by their distinct urinary porphyrin patterns (24) . Strik refined these pattern classifications (Table 1 ) and has used these for recognizing early effects from exposure to porphyrinogenic chemicals (25) .
In animals or humans exposed to porphyrinogenic chemicals, a normal liver and urinary porphyrin pattern change into early liver disease and coproporphyrinuria may be observed. As the liver disease from chemical damage develops, the urinary patterns change progressively in steps to: a type A pattern in which the uroporphyrins or heptacarboxylporphyrins are present in amounts less than coproporphyrin; a type B pattern Plots of the periodic urinary porphyrin output of groups of female Sherman rats that were given either 1 g/kg or 0 g/kg (control) of PBB. The urinary porphyrin output is expressed as the ratios of uroporphyrin to coproporphyrin (U/C) and heptacarboxylporphyrin to coproporphyrin (Hp/C). The urinary porphyrins were determined by a previously reported procedure (9) .
phyrin. These latter patterns (C and D) are observed in porphyria cutanea tarda. As perhaps might be expected, the uroporphyrin and heptacarboxylporphyrin are the two porphyrins found in porphyric liver tissue (26) .
With the development of HPLC, determining these urinary porphyrin patterns has become much easier, less time-consuming, and more adaptable to routine analysis.
All free porphyrin acids can be quantitatively analyzed by ion-pair chromatography with isocratic elution in less than 15 min, and the pattern can be assessed to identi'fy abnormal hepatic conditions (9) (Fig. 3) . These analyses can be used to follow the development of CHP, as in Figure 4 , where the urinary outputs of groups of female rats given 1 g/kg of PBB (Firemaster) (23) .
In our studies of groups exposed to porphyrinogenic chemicals, we have not observed the clear differences in urinary porphyrin patterns that Strik (22) and Doss (23) observed: 47% and 75% abnormal patterns, respectively Generally, 80 to 90% of our exposed groups had normal patterns, and coproporphyrinuria occurred about equally (5-8%) patterns were clearly associated only with PBB exposure. This does not mean that the type A pattern observed among the PBB-exposed animals was not produced by the PBB, but normal variations in control animals made it impossible to distinguish such effects with our small groups.
Conclusions
To evaluate the utility of urinary porphyrin patterns as a tool for recognizing exposure to PHAs, investigators must follow a population in which exposure has been recent and well documented. A comparable control population should also be selected so that any significant difference in porphyrin patterns and other biochemical values can be readily discerned.
Urine samples must be preserved properly (9) and must be analyzed by HPLC (or TLC) with proper quality control measures to provide the needed specificity. Investigators should also note exposure to alcohol and estrogenic substances, which are also porphyrinogenic agents. All cases in which PCT has been confirmed or is suspected should be assayed for erythrocyte UPD activity. A normal value, with complementary absence of PCT in family members, will likely indicate that the PCT was acquired from chemical exposure. Perhaps with the use of these and other techniques, chemically induced disease can be more clearly defined.
